CAR-T immunotherapy for cancer represents a successful alternative to classic cancer treatment. It is very successful with the haematological malignancies such as different lymphomas and acute lymphoblastic leukemia, however not so much with solid tumors, which still represent a challenge. Contributors that lower response rates are mainly T-cell exhaustion, senescence and inhibitory tumor microenvironment. That is why researchers are looking for a solution by adding domains to chimeric antigen receptor which would affect efficiency of the therapy- meaning higher activity and longer persistence, where negative aspects of the CAR-T immunotherapy would not be increased. To modulate CAR-T immunotherapy synthetic biology tools are used. Our aim was to create CD19 CAR receptor which would express domains from MyD88 adapter protein, a key mediator of innate immunity, in addition to traditional receptor elements. By using different methods we got an insight into the effect of such a receptor on activity of modified cells when stimulated correctly. We also got an insight into expression of receptor and expression of inhibitor of the key transcription factors NF-κB, IκBα. We observed higher activity, receptor expression on the cell membrane and different IκBα expression at different stimulation time.
|
